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oAbstract
Purpose: Microvascular thrombosis during septic conditions is of essential clinical
relevance, but the pathomechanisms are not yet completely understood. The
purpose of this study was to study the distinguished differentiation of the
interactions of inflammation and coagulation using antithrombin (AT), a mediator of
anticoagulation and anti-inflammation.
Methods: Using a thrombosis model in a cremaster muscle preparation of male
C57Bl/6J mice (n = 83), we quantitatively assessed microvascular thrombus formation
by using intravital fluorescence microscopy. Experimental groups consisted of
animals treated with AT or with tryptophan49-blocked AT (TrypAT), which exerts only
anticoagulant but no anti-inflammatory effects. To further see whether endothelial
glycosaminoglycan (GAG) binding with consecutive prostacyclin (PGI2) release is
mandatory for the anticoagulant process of AT, animals were administered heparin
or indomethacin either alone or in combination with AT.
Results: The antithrombotic capacity of AT significantly differs in the experimental
groups in which anti-inflammation was antagonized. This is given by the significantly
prolonged occlusion times (p < 0.05) and higher patency rates in case of application
of AT alone; while all other groups in which the anti-inflammatory action of AT was
blocked by TrypAT, heparin or indomethacin revealed thrombus kinetics comparable
to controls.
Conclusions: The anti-inflammatory influence of AT is essentially linked to its
anticoagulant effect in the microvascular system. Those specifications of the
active profile of AT characterize the intimate interactions of the anticoagulant
and anti-inflammatory pathways. This might be of relevance for AT as a therapeutic
agent in critically diseased patients and the clinical understanding of microvascular
thrombosis.
Keywords: Thrombosis; Microvasculature; Light-dye model; Ferric chloride; Cremaster
muscleBackground
The close interactions of coagulation and inflammation in the microvascular system
are not yet understood in total but are of high relevance especially for the treatment of
sepsis, septic shock, and associated phenomena like disseminated intravascular coagu-
lation (DIC). During this complex and fast-acting pathomechanism in septic disorders,2015 Sorg et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
reativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
riginal work is properly credited.
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change significantly and can therefore be used as powerful prognostic markers of DIC
[1, 2]. In this context, the expectations on the high-dosed supplementation of anti-
thrombin (AT), one of the most important human physiologic coagulation inhibitors,
were once high. AT application, however, could not induce a significant survival benefit
in the KyberSept-trial [3] and is, therefore, globally not recommended in sepsis therapy
guidelines [4, 5]. The failure of AT might have been linked to its specific interaction to
heparin, as it could be shown that heparin irreversibly blocks the binding site of AT at
the endothelium, inhibiting the anti-inflammatory release of prostacyclin [6, 7]. Fur-
thermore, this close interaction could also be demonstrated in a prospectively defined
subset of patients with high-dosed AT in the KyberSept-trial, who did not receive con-
comitant heparin-treatment for thrombosis prophylaxis [3, 6–8]. Only in the AT alone
group mortality has been significantly reduced, suggesting an adverse reaction of AT
with heparin [3, 6–8]. Recently, it could be shown that moderate doses of AT in septic
patients could increase the patient recovery from DIC without major bleeding disorders
[9]. In parallel, our group was also able to show in experimental models that high-dose
AT application without heparin sufficiently prevented thrombosis under physiological
as well as endotoxemic conditions [10, 11]. AT is a well-explored mediator with a dual
profile of action including its anti-inflammatory as well as anticoagulant effects. The
aim of the following study, therefore, was to further elucidate interactions between the
coagulation and inflammatory system in the microvasculature using AT as lead sub-
stance due to its influence on both systems and to further evaluate which of AT’s active
profiles are crucial for the anticoagulant effectiveness.Methods
Animals
A total of 83 male C57Bl/6J mice (10–12 weeks old, 20–30 g body weight (bw)) have
been used for the study. The animals were housed in standard laboratories with a 12 h
light-dark cycle and had ad libitum access to chow and water. All experiments were
conducted in accordance with guidelines for the Care and Use of Laboratory Animals
and the Institutional Animal Care and Use Committee (University of Rostock, Medical
Faculty, Rostock, Germany).Mouse cremaster muscle preparation
For the study of microvascular thrombus formation in vivo, we used the open cremas-
ter muscle preparation, as previously described by our group [10, 11]. Mice were
anesthetized by an intraperitoneal injection of ketamine (90 mg/kg bw) and xylazine
(25 mg/kg bw). Prior to the preparation of the cremaster muscle, animals were placed
on a heating pad and the insertion of a fine polyethylene catheter (PE10, 0.28 mm in-
ternal diameter) into the right jugular vein served to apply drugs and fluorescent dyes.
A midline incision of the skin and fascia was made over the ventral aspect of the scro-
tum and extended up to the inguinal fold and to the distal end of the scrotum. The
incised tissues were retracted to expose the cremaster muscle that was maintained
under gentle traction to carefully separate the remaining connective tissue by blunt dis-
section from the cremaster. Afterwards, the cremaster muscle was incised, avoiding
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which also served to spread the muscle. After dissection of the vessel connecting the
cremaster and the testis, the epididymis and testis were put to the side of the prepar-
ation. After preparation of the cremaster muscle, the animals were allowed to recover
from surgery for 15 min.Intravital microscopy and thrombus induction
After IV injection of 0.1 mL 5 % fluorescein isothiocyanate (FITC)-labeled dextran
(MW 150.000 Da, Sigma), 0.1 mL 0.2 % rhodamine 6G (MW 476 Da, Sigma), and sub-
sequent circulation for 30 s, the cremaster muscle microcirculation was visualized by
intravital fluorescence microscopy using a Zeiss microscope (Zeiss Axiotech Vario, Jena,
Germany). The epi-illumination setup included a 100 W HBO mercury lamp and an
illuminator equipped with a blue (450 to 490 nm/>520 nm excitation/emission wave-
lengths) and green filter set (530 to 560 nm/>580 nm). Microscopic images were re-
corded by a charge-coupled-device video camera (FK 6990A-IQ, Pieper, Berlin,
Germany) and stored on videotapes for off-line evaluation. Using a ×63 water
immersion objective (Achroplan ×20/0.5 W, Zeiss), blood flow was monitored in indi-
vidual venules. Thrombus formation was induced in randomly chosen venules by con-
stant superfusion with 25 μL ferric chloride every 60 s (12.5 mmol/L; Sigma-Chemical,
Deisenhofen, Germany). Additionally, the light-dye model was used in which the expos-
ure of FITC-dextran to blue light results in the release of free oxygen radicals and con-
secutive damage of the endothelial cell. Recording of vessels was stopped after blood
flow in the vessel ceased for at least 45 s due to complete vessel occlusion (CVO).Microcirculatory analysis
Kinetics of intravascular thrombus formation has been quantified off-line by analyzing
the videotaped images using the computer-assisted image analysis system CapImage
(Dr. Zeintl Software, Heidelberg, Germany). Thrombus formation was quantified by
assessing the time until sustained cessation of blood flow due to complete vessel occlu-
sion, as well as the percentage of vessels which were completely clogged after 20 min
of continuous thrombus induction. If a vessel did not clog within 20 min of continuous
ferric chloride exposure, the observation was stopped, and the vessel was considered as
patent. Venular patency rate describes the patent vessels in percent of all venules under
investigation. Microcirculatory analysis further included the determination of vessel
diameter, thrombus height, red blood cell velocity (RBCV), and additionally, the calcu-
lation of vascular wall shear rates (γ), based on the Newtonian definition γ = 8 × V/D,
with V representing the red blood cell centerline velocity divided by 1.6, according to
the Baker-Wayland factor, and D representing the individual inner vessel diameter.Experimental design and experimental groups
Twenty minutes before induction of thrombosis (TI), animals received either a single
IV-bolus of AT (250 IU/kg bw; Kybernin HS, CSL Behring, Marburg, Germany; n = 16),
or saline (control; n = 16) corresponding to the fluid amount applied in the verum
experiments (Fig. 1, Table 1). In a third group of animals, tryptophan49-blocked AT
(TrypAT; 250 IU/kg; CSL Behring, Marburg, Germany; n = 9) was administered 20 min
Fig. 1 In vivo protocol experimental groups. Flow chart displaying the in vivo protocol for the different
experimental groups in C57B1/6J mice. Before intravital fluorescence microscopy (IVM) and thrombosis
induction (TI), anesthetized mice received different applications of the respective substances as mentioned
in the dosing regimen of Table 1
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formed according to the method of Blackburn et al. [12]; Tryp49 was labeled by using
dimethyl (2-hydroxy-5-nitrobenzyl) sulfonium bromide. Because Tryp49-blocked AT
evokes equivalent anticoagulant effects, considering actions depending on the progres-
sive inhibition of proteases and simultaneously shows inability to interact with glycos-
aminoglycans (GAG), this tool allowed us to discriminate between AT effects on
the coagulation and on the microcirculation, i.e., anti-inflammatory ability of non-
blocked AT. To elucidate the distinct anti-inflammatory effects of AT on venous
thrombus formation and the interaction with prostacyclin, we examined the cyclo-
oxygenase inhibitor indomethacin (5 mg/kg sc; Liometacen, Promedica, Parma,
Italy) in combination with AT (Indo + AT, n = 16). In addition, heparin (100 IU/kg
bw; Liquemin N, Hoffmann-La Roche AG, Grenzach-Wyhlen, Germany) was com-
bined with AT (Hep + AT; n = 8). The combination of AT and heparin was applied
to study whether the antithrombotic effect of AT is essentially linked to the endo-
thelial GAG binding. As respective control groups, single heparin (n = 9) and indo-
methacin treatment (n = 9) has been studied in the dosages as mentioned above
(Fig. 1).
Statistical analysis
Data were analyzed for normality and equal variance across the groups. Differences be-
tween groups were assessed using 1-way ANOVA followed by the appropriate post-hoc
comparison test (all pairwise). All data revealed normal distribution and were expressed
as means ± SEM. Overall statistical significance was set at p < 0.05. Statistics and graph-
ics were performed using the software packages SigmaStat and SigmaPlot (Jandel
Corporation, San Rafael, CA, USA).
Results
Thrombus formation
With continuous ferric chloride superfusion and light exposure, thrombus forma-
tion was initiated, and a constant thrombus growth has been observed (Fig. 2). To
analyze the influence on microcirculatory parameters, we acquired values for
thrombus height, RBCV, and wall shear rate. The relation between RBCV and
thrombus height demonstrates a negative correlation throughout all groups. With
increasing thrombus height, the RBCV is decreasing (data not shown; y = −0.02 ×
Table 1 In vivo protocol and experimental groups
Groups 1. dose 2. dose 3. dose
Subcutaneous Intravenous Intravenous
Control NaCl (0.9 %) NaCl (0.9 %) NaCl (0.9 %)
AT NaCl (0.9 %) NaCl (0.9 %) AT (250 IU/kg)
TrypAT NaCl (0.9 %) NaCl (0.9 %) TrypAT (250 IU/kg)
Indo indo (5 mg/kg) NaCl (0.9 %) NaCl (0.9 %)
Indo + AT indo (5 mg/kg) NaCl (0.9 %) AT (250 IU/kg)
Heparin NaCl (0.9 %) heparin (100 IU/kg) NaCl (0.9 %)
Heparin + AT NaCl (0.9 %) heparin (100 IU/kg) AT (250 IU/kg)
Flow chart displaying the in vivo protocol for the different experimental groups in C57Bl/6J mice. Before intravital
fluorescence microscopy (IVM) and thrombosis induction (TI), anesthetized mice received different applications of the
respective substances
AT antithrombin, Indo indomethacin, TrypAT tryptophane49-modified AT
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cantly differ to each other showing standardized TI among all groups. The RBCV
is constantly decreasing in all groups from ~1.0 mm/s to ~0.65 mm/s during the
time of continuous TI. Furthermore, there was no significant influence on the re-
sults of the wall shear rate between all groups.
Patency rate
The patency rate is defined as the percentage of patent vessels at a certain time point
during TI. The application of physiologic saline and dual TI led to a patency rate of
13 % of investigated vessels after 1200 s (Fig. 3). The application of AT, however, was
far more effective as all vessels under investigation were found patent at 600 s (100 %)Fig. 2 Thrombus growth. Representative intravital microscopic images of a mouse cremaster venule showing
a growing thrombus at four different time points (A = 0 s; B = 438 s; C = 565 s; D = 915 s) during thrombus
induction (magnification ×630). The arrows indicate the direction of the blood flow
Fig. 3 Patency rate of venules. Cumulative Kaplan-Meier patency rate of venules after induction of thrombus
formation in cremaster muscle preparations of mice treated with either physiological saline (control),
antithrombin (250 IU/kg; AT), tryptophan49-blocked AT (250 IU/kg; TrypAT), indomethacin (5 mg/kg;
indo), indomethacin plus AT (indo + AT), heparin (100 IU/kg), or heparin plus AT (hep + AT). Data is
given as the following single values: Kaplan-Meier-Analysis (Gehan-Breslow Test), * p < 0.05 vs. AT
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a patency rate of 38 % in the AT group (Fig. 3). TrypAT and indomethacin pre-
treatment led to a patency rate of 33 % after 1200 s. The application of heparin and
heparin in combination with AT or indomethacin and indomethacin plus AT led to pa-
tency rates of about 20 % after 1200 s of continuous TI (Fig. 3).Complete vessel occlusion (CVO)
CVO includes all clogged vessels within the investigation time of 1200 s and describes
the mean time that was necessary for irreversible occlusion of a vessel by a thrombus
(Fig. 4). In control animals, CVO was observed after 440 ± 54 s of ferric chloride and
light exposure. AT application presented with major antithrombotic effectiveness, as
given by a significant and more than 2-fold prolongation of the time (964 ± 69 s),
which was needed for CVO (Fig. 4; p < 0.05 vs. control). To further analyze whether
the antithrombotic effect is mandatorily linked to the binding of AT to GAGs, TrypAT
has been used. Application of TrypAT showed significantly shorter occlusion times
than AT (485 ± 79 s), which were comparable to that in controls, indicating that the
GAG binding is being considered responsible for the observed anti-inflammatory cap-
ability of AT but is also necessary for its anticoagulant function. Additionally, we could
observe that the combined application of indomethacin and AT (482 ± 57 s) as well as
the indomethacin application alone (497 ± 108 s) could not prolong microvascular
thrombus formation as given by similar values for CVO to those in controls. The
Fig. 4 Complete vessel occlusion time. Time until complete occlusion of venules after induction of
thrombus formation in cremaster muscle preparations of mice treated with either physiological saline
(control), antithrombin (250 IU/kg; AT), tryptophan49-blocked AT (250 IU/kg; TrypAT), indomethacin
(5 mg/kg; indo), indomethacin plus AT (indo + AT), heparin (100 IU/kg), or heparin plus AT (hep + AT).
Data is given as means ± SEM; ANOVA, post-hoc comparison; * p < 0.01 vs. control; # p < 0.01 vs. AT
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control group (790 ± 98 s, p < 0.05 vs. control); however, the effect is below the single
AT application results.Discussion
Microvascular thrombosis is a pathophysiologic key event during sepsis, due to the
cross-activation of the coagulation cascade and the systemic pro-inflammatory re-
sponse. These effects are mainly based on the Virchow’s triad, composed of endothelial
injury as well as abnormal blood flow and blood constituents. As the ICU patient in
general is at a high risk of thrombosis and benefits from thrombosis prophylaxis, it is
still of on-going interest to study thrombus formation under experimental conditions
providing new mechanistic insights of the interactions between the coagulation and in-
flammatory system, giving advice for the optimization of the clinical therapy.Methodological considerations
To test the effects of different substances on their potential to prevent thrombus for-
mation, many distinct models exist [13]. The herein used mouse cremaster muscle
preparation is a well-characterized and standardized model to study the kinetics of
thrombus formation in the microcirculation. It allows the direct visualization of the
process of thrombus formation by intravital fluorescence microscopy in both trans-
and epi-illumination techniques. Thrombus formation was initiated by two different
models. Ferric chloride (FeCl3) superfusion is not primarily based on oxidant stress-
induced endothelial cell damage. The diffusion of FeCl3 through the vessel wall results
in denudation of the endothelial cell and in the appearance of ferric-ion filled spherical
bodies, which induce platelet adhesion and thrombin formation [14, 15]. Additionally,
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the intravital microscope [16, 17]. Both models result in local endothelial cell damage
leading to the exposure of subendothelial matrix components (tissue factor; P-selectin).
This supports the deposition of blood cellular components, representing the ideal site
for thrombus formation in micro- as well as macro-vessels [13]. Furthermore, it in-
volves the release/formation of fibrinogen/fibrin, von Willebrand factor, fibronectin,
and the glycoprotein IIb/IIIa [18–20]. Therefore, the combination of the light-dye
model with the exposure of vessels to ferric chloride for thrombosis induction repre-
sents a common and widely used model to study, in particular, molecular and cellular
mechanisms of microvascular thrombus formation [21–23] and to study the association
between inflammation and thrombosis.
Clinical studies suggest an AT supplementation to achieve a plasma AT activity
of >120 % during the observational period [24, 25]. Early studies by Fourrier et al.
[26] in septic shock patients with disseminated intravascular coagulation (DIC) re-
ceived 90–120 IU/kg/d AT. This dosage could already reduce mortality by 44 % in
AT-treated patients vs. the control group. The importance of an effective AT
plasma activity could additionally be shown in many clinical studies of low AT
plasma activity and bad outcomes of septic patients [26–28]. Furthermore, Ranucci
et al. [29] could demonstrate that low AT levels in cardiac surgery patients at
hospitalization are associated with a significant prolongation of intensive care treat-
ment. Therefore, we have chosen a dose of 250 IU/kg bw which results in plasma
concentrations comparable to those achieved in clinical practice and that have been
shown to possess therapeutic, antithrombotic, and anti-inflammatory potential in
previous studies of our group [10, 11, 30–32]. With this dosing regimen, we have
been able to achieve high physiological plasma levels of approximately 120 % after
application of 250 IU/kg bw. [11]. In addition, Uchiba and colleagues could dem-
onstrate that lower doses of AT (50 and 100 IU/kg bw) significantly inhibited co-
agulation abnormalities, but however, failed to prevent pulmonary accumulation of
leukocytes and subsequent pulmonary vascular injury [33].
The pre-treatment with indomethacin results in an inhibition of the cyclooxygenase
pathway preventing the formation of prostacyclin [34]. In a previous study, we could
show that the combination of AT with indomethacin completely abolished the anti-
inflammatory effects of AT on the microcirculation [30]. This has been in line with
other findings, where AT has been shown to promote prostacyclin release from endo-
thelial cells [35]. Therefore, the primary target cell of the indomethacin pre-treatment
was the endothelial cell. However, COX inhibition also targets platelets, which is asso-
ciated with some prothrombotic tendency [36–38].Anticoagulant profile of AT
In patients with trauma, shock, and sepsis, the AT activity is decreased due to its con-
sumption via complex formation with clotting factors and enzymatic degradation [1, 2, 9].
Many experimental as well as clinical trials demonstrated that the supplementation of AT
exerts additional anti-inflammatory effects [5, 24, 25, 39–41]; however, in the clinical set-
ting of sepsis therapy, AT is not recommended as high-dose AT was associated with an
increased risk of bleeding when administered with heparin [4]. Although heparin is
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taneously AT-mediated anti-inflammatory effects [31, 42–44]. This observation was also
found during the KyberSept-trial [3, 6, 8] where the combination of AT and heparin failed
to improve the mortality of patients with severe sepsis.
While the anti-inflammatory activity of AT seems to be independent from its anti-
coagulant function [32], our data demonstrates that the effects of AT in the micro-
vascular system crucially depend on its anti-inflammatory mode of action. With the
inhibition of the anti-inflammatory activity of AT by a specific blocking of the end-
product synthesis of PGI2 (indomethacin) or inhibiting the GAG binding (TrypAT,
heparin), the CVO results are comparable with control animals. Binding of AT to endo-
thelial GAGs is consecutively associated with PGI2 release. This step has been con-
firmed by studies, demonstrating the abrogation of the beneficial effects of AT by
inhibition of PGI2 release with indomethacin in pulmonary vascular injury and systemic
endotoxemia [30, 34]. As TrypAT does not display any anti-inflammatory properties
due to an ineffective heparin-binding ability at the endothelial surface [45], its adminis-
tration might enable the discrimination between endothelium-related effects of AT and
GAG-independent mediation of anticoagulation [32]. This specific effect of TrypAT
has been shown in several previous studies, such as gastric mucosal injury [46], renal
injury [47], pulmonary vascular injury [48, 49], and spinal cord injury [50]. Conse-
quently, we used TrypAT to discriminate between the two effects of AT, i.e., anticoagu-
lation and anti-inflammation. In our study, the previous suggestion that native AT and
TrypAT might have similar anticoagulant activities, as given by the similar improve-
ment of coagulation abnormalities, could not be confirmed by our in vivo results,
showing that TrypAT-treated animals presented significantly faster thrombosis forma-
tion compared to animals treated with native AT. This implies the decisive role of the
AT-GAG interaction at the microvascular endothelial surface also for the ATs anti-
coagulant effect. Despite the optimized modification by Blackburn et al. [12] resulting
in TrypAT, which is used to differentiate between specific AT effects at the endothe-
lium and in the microcirculation, it cannot be ruled out that also—at least in part—-
other tryptophane residues might be blocked. This might lead to an alteration of the
heparin-dependent acceleration of thrombin-modified AT interactions as well; however,
it is not completely abolished [51]. This underscores the results of our study, as we
could not confirm the previous suggestion that native AT and TrypAT might have simi-
lar anticoagulant activities as given by the similar improvement of coagulation abnor-
malities [32]. TrypAT-treated animals presented significantly faster thrombosis
formation compared to animals treated with native AT, implying the decisive role of
the AT-GAG interaction at the microvascular endothelial surface for anticoagulation.
It is well known that AT is a pleiotropic inhibitor of the activated coagulation cascade
and that binding of heparin to AT seems to be a prerequisite for enhanced anticoagu-
lant effects [42]. Factor Xa-inhibition by AT deserves a unique heparin pentasaccharide
sequence, whereas longer polysaccharide chain heparins are required to enhance the in-
hibition of thrombin by AT [43, 52, 53]. The observation that the combination of AT
plus heparin in our study did not present a prolongation of thrombus formation chal-
lenges this view and might be explained as follows. On the endothelial surface, localized
GAGs are also comprised of heparan sulfates and heparin-like structures, which exert
the same effect on AT as heparin in the blood [42, 54]. These heparin-like binding sites
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be the cause for the microcirculation being the preferential site of AT action. The coun-
teraction of AT by heparin has so far only been described for the anti-inflammatory ac-
tion, as heparin seems to diminish the vascular defense shield by keeping AT away
from its cellular binding sites [42, 43]. While heparin and AT compete for these binding
sites, exogenous administration of heparin might interfere not only with the anti-
inflammatory but also in part with the anticoagulant activity of AT, as combined ad-
ministration of heparin and AT was not able to achieve similar protection of thrombus
formation as AT alone, which is displayed by the shorter CVO times. Furthermore, the
heparin data is in line with previously published results by our own and other groups,
showing that heparin in the applied dosage is not associated with changes in venular
thrombus formation times [11, 55, 57–59]. However, at higher doses, heparin may
also promote the activation of platelets and clot formation by interacting with
platelet factor 4 [60, 61]. Our data reveals the essential importance of endothelial
AT-GAG interactions for microvascular thrombosis. The competing situation be-
tween heparin and AT for endothelial GAGs is of crucial relevance, as AT is not
able to trigger the release of PGI2 from the endothelium after the GAGs have been
irreversibly blocked by heparin (Fig. 5).
In the context of inflammation and coagulation, there is mounting evidence that both
cascades are not independently acting pathways [62–66]. Rather there is a multifaceted
crosslink between the coagulation cascade, the inflammatory system, and the local
endothelium. The anti-inflammatory potential of AT is directly linked to the cyclooxy-
genase pathway [32] as in a second hit model of severe endotoxemia the pre-treatment
with indomethacin completely abolished the protective effects of AT on leukocyte-Fig. 5 Function of antithrombin. Schematic overview of the anticoagulant function of antithrombin (AT)
and the mediation of anti-inflammation through glycosaminoglycan (GAG) binding at the endothelial cell
(EC) with subsequent release of prostacyclin (PGI2). Until now, it was not clarified whether the antithrombotic
potency of AT is exclusively based on its solitary anticoagulant capacity or if it might also depend on its
anti-inflammatory mode of action. The data in the here-presented study indicates that the anti-inflammatory
property of AT is a prerequisite for mediating adequate anticoagulation
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sults of the here-presented study, the cyclooxygenase pathway which is initiated by the
binding of AT to the endothelium, might also be suggested to be essential for the anti-
coagulant capability of AT as well because indomethacin pre-treatment attenuated AT
effects to prolong thrombus formation.Conclusions
In conclusion, we have been able to characterize the distinct anticoagulant profile of AT
in a murine model of microvascular thrombosis. Our data indicates that the anti-
inflammatory potential of AT is indispensable for the adequate mediation of anticoagula-
tion within the microvasculature. These intricate interactions are of important relevance
for the therapeutical options of septic disorders and once again support the intimate rela-
tionship between the coagulation cascade and the inflammatory system.
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